| Year |
Citation |
Score |
| 2021 |
Wang YL, Lee CC, Shen YC, Lin PL, Wu WR, Lin YZ, Cheng WC, Chang H, Hung Y, Cho YC, Liu LC, Xia WY, Ji JH, Liang JA, Chiang SF, ... ... Hung MC, et al. Evading immune surveillance via tyrosine phosphorylation of nuclear PCNA. Cell Reports. 36: 109537. PMID 34433039 DOI: 10.1016/j.celrep.2021.109537 |
0.301 |
|
| 2021 |
Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, ... ... Hung MC, et al. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature Communications. 12: 2788. PMID 33986289 DOI: 10.1038/s41467-021-23075-2 |
0.316 |
|
| 2021 |
Cho J, Min HY, Lee HJ, Hyun SY, Sim JY, Noh M, Hwang SJ, Park SH, Boo HJ, Lee HJ, Hong S, Park RW, Shin YK, Hung MC, Lee HY. RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. The Journal of Clinical Investigation. 131. PMID 33393490 DOI: 10.1172/JCI136779 |
0.347 |
|
| 2020 |
Chen M, Xia W, Dong Q, Du Y, Wang H, Tapia C, Wei Y, Han Y, Chu Y, Yam C, Gao Y, Wang Y, Meric-Bernstam F, Liu J, Wang S, ... ... Hung M, et al. Abstract 5682: Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances Cancer Research. 80: 5682-5682. DOI: 10.1158/1538-7445.Am2020-5682 |
0.358 |
|
| 2019 |
Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, et al. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene. PMID 31554935 DOI: 10.1038/S41388-019-1010-4 |
0.348 |
|
| 2019 |
Wang P, Gong Y, Guo T, Li M, Fang L, Yin S, Kamran M, Liu Y, Xu J, Xu L, Peng F, Xue X, Yang M, Hung MC, Lam EW, et al. Activation of Aurora A kinase increases YAP stability via blockage of autophagy. Cell Death & Disease. 10: 432. PMID 31160567 DOI: 10.1038/s41419-019-1664-4 |
0.301 |
|
| 2019 |
Liu YL, Chou CK, Kim M, Vasisht R, Kuo YA, Ang P, Liu C, Perillo EP, Chen YA, Blocher K, Horng H, Chen YI, Nguyen DT, Yankeelov TE, Hung MC, et al. Assessing metastatic potential of breast cancer cells based on EGFR dynamics. Scientific Reports. 9: 3395. PMID 30833579 DOI: 10.1038/S41598-018-37625-0 |
0.411 |
|
| 2018 |
Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, Lee H, Zhou Z, Gan B, Nakagawa S, Ellis MJ, ... ... Hung MC, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nature Genetics. PMID 30349115 DOI: 10.1038/S41588-018-0252-3 |
0.31 |
|
| 2018 |
Xing Z, Zhang Y, Liang K, Yan L, Xiang Y, Li C, Hu Q, Jin F, Putluri V, Putluri N, Coarfa C, Sreekumar A, Park PK, Nguyen TK, Wang S, ... ... Hung MC, et al. Expression of long non-coding RNA YIYA promotes glycolysis in breast cancer. Cancer Research. PMID 29967256 DOI: 10.1158/0008-5472.Can-17-0385 |
0.332 |
|
| 2018 |
Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, ... ... Hung MC, et al. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Reports. 23: 823-837. PMID 29669287 DOI: 10.1016/J.Celrep.2018.03.078 |
0.33 |
|
| 2017 |
Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene. PMID 28925391 DOI: 10.1038/Onc.2017.311 |
0.325 |
|
| 2017 |
Nakai K, Xia W, Liao HW, Saito M, Hung MC, Yamaguchi H. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer (Tokyo, Japan). PMID 28643125 DOI: 10.1007/s12282-017-0790-z |
0.302 |
|
| 2017 |
Hsu DS, Hwang WL, Yuh CH, Chu CH, Ho YH, Chen PB, Lin HS, Lin HK, Wu SP, Lin CY, Hsu WH, Lan HY, Wang HJ, Tai SK, Hung MC, et al. Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28196873 DOI: 10.1158/1078-0432.CCR-16-1955 |
0.416 |
|
| 2017 |
Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, ... ... Hung MC, et al. Metastasis regulation by PPARD expression in cancer cells. Jci Insight. 2: e91419. PMID 28097239 DOI: 10.1172/Jci.Insight.91419 |
0.343 |
|
| 2016 |
Rezaeian AH, Li CF, Wu CY, Zhang X, Delacerda J, You MJ, Han F, Cai Z, Jeong YS, Jin G, Phan L, Chou PC, Lee MH, Hung MC, Sarbassov D, et al. A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1α activation, tumorigenesis and metastasis. Nature Cell Biology. PMID 27918549 DOI: 10.1038/ncb3445 |
0.454 |
|
| 2016 |
Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Reviews. PMID 27913999 DOI: 10.1007/s10555-016-9649-6 |
0.324 |
|
| 2016 |
Chang SS, Yamaguchi H, Xia W, Lim SO, Khotskaya Y, Wu Y, Chang WC, Liu Q, Hung MC. Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene. PMID 27593935 DOI: 10.1038/onc.2016.292 |
0.325 |
|
| 2016 |
Ko HW, Lee HH, Huo L, Xia W, Yang CC, Hsu JL, Li LY, Lai CC, Chan LC, Cheng CC, Labaff AM, Liao HW, Lim SO, Li CW, Wei Y, ... ... Hung MC, et al. GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. PMID 27494834 DOI: 10.18632/oncotarget.11008 |
0.333 |
|
| 2016 |
Liu CC, Lin SP, Hsu HS, Yang SH, Lin CH, Yang MH, Hung MC, Hung SC. Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells. Nature Communications. 7: 11798. PMID 27306323 DOI: 10.1038/ncomms11798 |
0.309 |
|
| 2016 |
Chang TY, Chen HA, Chiu CF, Chang YW, Kuo TC, Tseng PC, Wang W, Hung MC, Su JL. Dicer elicits paclitaxel chemosensitization and suppresses cancer stemness in breast cancer by repressing AXL. Cancer Research. PMID 27216190 DOI: 10.1158/0008-5472.CAN-15-2555 |
0.323 |
|
| 2016 |
Chang CC, Zhang C, Zhang Q, Sahin O, Wang H, Xu J, Xiao Y, Zhang J, Rehman SK, Li P, Hung MC, Behbod F, Yu D. Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. PMID 27150057 DOI: 10.18632/Oncotarget.9136 |
0.322 |
|
| 2016 |
Zheng F, Yue C, Li G, He B, Cheng W, Wang X, Yan M, Long Z, Qiu W, Yuan Z, Xu J, Liu B, Shi Q, Lam EW, Hung MC, et al. Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nature Communications. 7: 10180. PMID 26782714 DOI: 10.1038/Ncomms10180 |
0.31 |
|
| 2016 |
Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, ... ... Hung MC, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. PMID 26779812 DOI: 10.1038/Nm.4032 |
0.333 |
|
| 2016 |
Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, ... ... Hung MC, et al. EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape. Cancer Research. PMID 26759242 DOI: 10.1158/0008-5472.Can-15-2478 |
0.336 |
|
| 2016 |
Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, ... ... Hung MC, et al. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation. Cancer Research. PMID 26759241 DOI: 10.1158/0008-5472.CAN-15-1941 |
0.34 |
|
| 2016 |
Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, Wei Y, Ma G, Park PK, Zhou J, Zhou Y, ... ... Hung MC, et al. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nature Cell Biology. PMID 26751287 DOI: 10.1038/Ncb3295 |
0.303 |
|
| 2015 |
Han B, Qu Y, Jin Y, Yu Y, Deng N, Wawrowsky K, Zhang X, Li N, Bose S, Wang Q, Sakkiah S, Abrol R, Jensen TW, Berman BP, Tanaka H, ... ... Hung MC, et al. FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer. Cell Reports. 13: 1046-1058. PMID 26565916 DOI: 10.1016/J.Celrep.2015.09.063 |
0.344 |
|
| 2015 |
Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, ... ... Hung MC, et al. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. PMID 26481148 DOI: 10.1016/J.Ccell.2015.09.008 |
0.316 |
|
| 2015 |
Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, ... ... Hung MC, et al. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. PMID 26212011 DOI: 10.1038/Onc.2015.279 |
0.314 |
|
| 2015 |
Chang YW, Tseng CF, Wang MY, Chang WC, Lee CC, Chen LT, Hung MC, Su JL. Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. Oncogene. PMID 26119938 DOI: 10.1038/onc.2015.214 |
0.301 |
|
| 2015 |
Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, ... ... Hung MC, et al. The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6: 7351. PMID 26081979 DOI: 10.1038/Ncomms8351 |
0.31 |
|
| 2015 |
Sorokin AV, Nair BC, Wei Y, Aziz KE, Evdokimova V, Hung MC, Chen J. Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis. Cancer Research. 75: 1846-58. PMID 25877877 DOI: 10.1158/0008-5472.Can-14-2718 |
0.367 |
|
| 2015 |
Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, et al. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular Oncology. 9: 586-600. PMID 25435280 DOI: 10.1016/J.Molonc.2014.10.011 |
0.302 |
|
| 2015 |
Nie L, Wei Y, LaBaff A, Yang C, Xia W, Huo L, Liu D, Hsu Y, Hortobagyi GN, Yao J, Kleer CG, Hung M. Abstract 2895: Phosphorylation of EZH2 at T416 by CDK2 promotes development of mammary tumors with basal-like phenotype Cancer Research. 75: 2895-2895. DOI: 10.1158/1538-7445.Am2015-2895 |
0.324 |
|
| 2014 |
Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, Park PK, Qin L, Wei Y, Hawke DH, Hung MC, Lin C, Yang L. lncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell. 159: 1110-25. PMID 25416949 DOI: 10.1016/j.cell.2014.10.013 |
0.303 |
|
| 2014 |
Chang YW, Chen HA, Tseng CF, Hong CC, Ma JT, Hung MC, Wu CH, Huang MT, Su JL. De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells. Oncotarget. 5: 10558-70. PMID 25301734 DOI: 10.18632/ONCOTARGET.2510 |
0.316 |
|
| 2014 |
Thirumurthi U, Shen J, Xia W, LaBaff AM, Wei Y, Li CW, Chang WC, Chen CH, Lin HK, Yu D, Hung MC. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Science Signaling. 7: ra71. PMID 25074979 DOI: 10.1126/Scisignal.2005076 |
0.344 |
|
| 2014 |
Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, ... ... Hung MC, et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Research. 74: 4822-35. PMID 24970481 DOI: 10.1158/0008-5472.Can-14-0584 |
0.308 |
|
| 2014 |
Chang YW, Hung MC, Su JL. The anti-tumor activity of E1A and its implications in cancer therapy. Archivum Immunologiae Et Therapiae Experimentalis. 62: 195-204. PMID 24504082 DOI: 10.1007/s00005-014-0273-2 |
0.315 |
|
| 2014 |
Khotskaya YB, Goverdhan A, Shen J, Sarvice MP, Chang S, Hsu M, Wei Y, Xia W, Steeg P, Yu D, Hung M. Abstract A49: S6K1 promotes invasiveness of breast cancer cells in a novel model of triple-negative breast cancer metastasis Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Modorg-A49 |
0.335 |
|
| 2014 |
Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Cascone T, Giri D, Kim J, Ye Y, Multani A, Chan C, Erez B, Saigal B, Lin H, ... ... Hung M, et al. Abstract 5146: The histone demethylase KDM2A is a new promoter of tumorigenesis, drug target and negative prognostic biomarker for non-small cell lung cancer Cancer Research. 74: 5146-5146. DOI: 10.1158/1538-7445.Am2014-5146 |
0.321 |
|
| 2014 |
Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Jin J, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Martin JF, ... ... Hung M, et al. Abstract 3896: The Hippo coactivator YAP1 upregulates SOX9 and endows cancer stem cell properties in non-transformed cells and esophageal cancer cells Cancer Research. 74: 3896-3896. DOI: 10.1158/1538-7445.Am2014-3896 |
0.307 |
|
| 2014 |
Hsu JL, Huo L, Li CW, Hsu YH, Wang Y, Hung MC. Cancer Gene Therapy by Tissue-specific and Cancer-targeting Promoters Cancer Gene Therapy by Viral and Non-Viral Vectors. 79-96. DOI: 10.1002/9781118501665.ch5 |
0.317 |
|
| 2013 |
Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, Wang M, Chen D, Sun Y, Hung MC, Chen J, Ma L. Deubiquitylation and stabilization of PTEN by USP13. Nature Cell Biology. 15: 1486-94. PMID 24270891 DOI: 10.1038/Ncb2874 |
0.312 |
|
| 2013 |
Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Research. 73: 6516-25. PMID 24014597 DOI: 10.1158/0008-5472.Can-13-0967 |
0.372 |
|
| 2013 |
Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 154: 556-68. PMID 23911321 DOI: 10.1016/j.cell.2013.06.048 |
0.317 |
|
| 2013 |
Yu YL, Chou RH, Liang JH, Chang WJ, Su KJ, Tseng YJ, Huang WC, Wang SC, Hung MC. Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides. Plos One. 8: e61362. PMID 23593472 DOI: 10.1371/journal.pone.0061362 |
0.335 |
|
| 2013 |
Yi P, Xia W, Wu RC, Lonard DM, Hung MC, O'Malley BW. SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes & Development. 27: 274-87. PMID 23388826 DOI: 10.1101/Gad.203760.112 |
0.332 |
|
| 2013 |
Hsia TC, Tu CY, Chen YJ, Wei YL, Yu MC, Hsu SC, Tsai SL, Chen WS, Yeh MH, Yen CJ, Yu YL, Huang TC, Huang CY, Hung MC, Huang WC. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Molecular Pharmacology. 83: 857-69. PMID 23355539 DOI: 10.1124/mol.112.082743 |
0.335 |
|
| 2013 |
Sher YP, Chang CM, Juo CG, Chen CT, Hsu JL, Lin CY, Han Z, Shiah SG, Hung MC. Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth. Oncogene. 32: 1082-90. PMID 22562248 DOI: 10.1038/Onc.2012.134 |
0.318 |
|
| 2013 |
Lim S, Li C, Chang S, Shen J, Hung M. Abstract 3027: A novel function of EGFR in epigenetic modulation via hMOF in breast cancer . Cancer Research. 73: 3027-3027. DOI: 10.1158/1538-7445.Am2013-3027 |
0.336 |
|
| 2013 |
Holder AM, Adkins F, Akcakanat A, Chen H, Do K, Hung M, Meric-Bernstam F. Abstract 1496: Epithelial to mesenchymal transition and rapamycin sensitivity in cancer cell lines. Cancer Research. 73: 1496-1496. DOI: 10.1158/1538-7445.Am2013-1496 |
0.307 |
|
| 2013 |
Zuo M, Rashid A, Churi C, Hung M, Javle M. Abstract C171: Novel therapeutic strategies targeting the hedgehog signaling pathway and mTOR pathway in biliary tract cancer (BTC). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C171 |
0.339 |
|
| 2012 |
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, Ma L. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nature Medicine. 18: 1511-7. PMID 23001183 DOI: 10.1038/Nm.2940 |
0.326 |
|
| 2012 |
Yu YL, Chou RH, Wu CH, Wang YN, Chang WJ, Tseng YJ, Chang WC, Lai CC, Lee HJ, Huo L, Chen CH, Hung MC. Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776. The Journal of Biological Chemistry. 287: 31015-26. PMID 22815474 DOI: 10.1074/jbc.M112.358077 |
0.316 |
|
| 2012 |
Yamaguchi H, Hsu JL, Hung MC. Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Frontiers in Oncology. 2: 15. PMID 22649777 DOI: 10.3389/fonc.2012.00015 |
0.317 |
|
| 2012 |
Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 149: 1098-111. PMID 22632973 DOI: 10.1016/J.Cell.2012.02.065 |
0.313 |
|
| 2012 |
Ouelaa-Benslama R, De Wever O, Hendrix A, Sabbah M, Lambein K, Land D, Prévost G, Bracke M, Hung MC, Larsen AK, Emami S, Gespach C. Identification of a GαGβγ, AKT and PKCα signalome associated with invasive growth in two genetic models of human breast cancer cell epithelial-to-mesenchymal transition International Journal of Oncology. 41: 189-200. PMID 22552300 DOI: 10.3892/ijo.2012.1457 |
0.353 |
|
| 2012 |
Yang WH, Lan HY, Huang CH, Tai SK, Tzeng CH, Kao SY, Wu KJ, Hung MC, Yang MH. RAC1 activation mediates Twist1-induced cancer cell migration. Nature Cell Biology. 14: 366-74. PMID 22407364 DOI: 10.1038/ncb2455 |
0.316 |
|
| 2012 |
Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, ... ... Hung MC, et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1 Cancer Research. 72: 1290-1300. PMID 22253230 DOI: 10.1158/0008-5472.CAN-11-3123 |
0.306 |
|
| 2012 |
Zhao H, Ho PC, Lo YH, Espejo A, Bedford MT, Hung MC, Wang SC. Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. Plos One. 7: e29416. PMID 22238610 DOI: 10.1371/Journal.Pone.0029416 |
0.342 |
|
| 2012 |
Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee HJ, Chang CJ, Chang WC, Hsu JM, Kuo HP, Xia W, Wei Y, Chiu PC, Chou CK, Du Y, ... ... Hung MC, et al. IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Molecular Cell. 45: 171-84. PMID 22196886 DOI: 10.1016/J.Molcel.2011.11.018 |
0.304 |
|
| 2012 |
Zhao HJ, Ho P, Lo Y, Espejo A, Bedford MT, Hung M, Wang S. Abstract 3036: Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer Cancer Research. 72: 3036-3036. DOI: 10.1158/1538-7445.Am2012-3036 |
0.347 |
|
| 2011 |
Chang CJ, Hung MC. The role of EZH2 in tumour progression. British Journal of Cancer. 106: 243-7. PMID 22187039 DOI: 10.1038/bjc.2011.551 |
0.308 |
|
| 2011 |
Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC, Hortobagyi GN, Hung MC. FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Research. 71: 6878-87. PMID 21911455 DOI: 10.1158/0008-5472.Can-11-0295 |
0.318 |
|
| 2011 |
Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell. 20: 341-56. PMID 21907925 DOI: 10.1016/J.Ccr.2011.07.017 |
0.321 |
|
| 2011 |
Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, Chang WC, Chang WC, Chen AJ, Tsai CH, Hung MC. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. The Journal of Biological Chemistry. 286: 20558-68. PMID 21487020 DOI: 10.1074/jbc.M111.240796 |
0.343 |
|
| 2011 |
Yang JY, Hung MC. Deciphering the role of forkhead transcription factors in cancer therapy. Current Drug Targets. 12: 1284-90. PMID 21443462 |
0.34 |
|
| 2011 |
Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell. 19: 86-100. PMID 21215703 DOI: 10.1016/J.Ccr.2010.10.035 |
0.351 |
|
| 2011 |
Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, ... ... Hung MC, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research. 71: 603-13. PMID 21123450 DOI: 10.1158/0008-5472.Can-10-3185 |
0.33 |
|
| 2011 |
Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, Luo X, Lazar A, Dicker A, Mills GB, Hung MC, et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 30: 457-70. PMID 20856200 DOI: 10.1038/Onc.2010.421 |
0.311 |
|
| 2011 |
Chang C, Hung M. Abstract 976: Hypoxic microenvironment promotes breast cancer stem cells through regulation of Polycomb protein expression Cancer Research. 71: 976-976. DOI: 10.1158/1538-7445.Am2011-976 |
0.357 |
|
| 2011 |
Khotskaya YB, Beck BH, Hurst DR, Hung M, Welch DR. Abstract 1438: Breast cancer metastasis suppressor 1 (BRMS1) suppresses attachment and spreading of breast cancer cells on 2D and 3D extracellular matrix components by altering focal adhesion-associated signaling Cancer Research. 71: 1438-1438. DOI: 10.1158/1538-7445.Am2011-1438 |
0.306 |
|
| 2011 |
Huo L, Wang Y, Xia W, Hsu S, Lai C, Li L, Chang W, Wang Y, Hsu M, Yu Y, Huang T, Ding Q, Chen C, Tsai C, Hung M. Abstract 1086: RHA plays an important role in EGFR-mediated gene transcription in cancer cells Cancer Research. 71: 1086-1086. DOI: 10.1158/1538-7445.Am2011-1086 |
0.312 |
|
| 2010 |
Jin Q, Yuan LX, Boulbes D, Baek JM, Wang YN, Gomez-Cabello D, Hawke DH, Yeung SC, Lee MH, Hortobagyi GN, Hung MC, Esteva FJ. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Research : Bcr. 12: R96. PMID 21080941 DOI: 10.1186/bcr2777 |
0.343 |
|
| 2010 |
Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 18: 423-35. PMID 21075308 DOI: 10.1016/j.ccr.2010.10.025 |
0.33 |
|
| 2010 |
Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Molecular Cancer Therapeutics. 9: 2770-84. PMID 20876744 DOI: 10.1158/1535-7163.MCT-09-0980 |
0.339 |
|
| 2010 |
Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung MC. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation Oncogene. 29: 5619-5629. PMID 20676141 DOI: 10.1038/Onc.2010.295 |
0.308 |
|
| 2010 |
Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Research. 70: 4709-18. PMID 20484037 DOI: 10.1158/0008-5472.Can-09-4524 |
0.326 |
|
| 2010 |
Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3171-81. PMID 20423983 DOI: 10.1158/1078-0432.Ccr-09-3171 |
0.333 |
|
| 2010 |
Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, Wu J, Nakayama KI, Kang HY, Huang HY, Hung MC, Pandolfi PP, Lin HK. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nature Cell Biology. 12: 457-67. PMID 20383141 DOI: 10.1038/Ncb2047 |
0.304 |
|
| 2010 |
Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, ... ... Hung MC, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Science Signaling. 3: ra9. PMID 20145209 DOI: 10.1126/Scisignal.2000590 |
0.308 |
|
| 2010 |
Yang P, Hung M, Wang Y, Tung E, Lee Y, Lee J. Abstract 499: EGFR expression correlates with response to photodynamic therapy in esophageal cancer cells Cancer Research. 70: 499-499. DOI: 10.1158/1538-7445.Am10-499 |
0.312 |
|
| 2009 |
Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer Clinical Cancer Research. 15: 6639-6648. PMID 19825949 DOI: 10.1158/1078-0432.CCR-09-0951 |
0.331 |
|
| 2009 |
Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 16: 195-207. PMID 19732720 DOI: 10.1016/J.Ccr.2009.08.010 |
0.309 |
|
| 2009 |
Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Molecular Cancer Research : McR. 7: 592-600. PMID 19372587 DOI: 10.1158/1541-7786.Mcr-08-0316 |
0.347 |
|
| 2009 |
Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Research. 69: 3425-32. PMID 19318578 DOI: 10.1158/0008-5472.Can-08-2765 |
0.336 |
|
| 2009 |
Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 752-7. PMID 19188143 DOI: 10.1158/1078-0432.CCR-08-0124 |
0.341 |
|
| 2009 |
Sher Y, Tzeng T, Kan S, Hsu J, Xie X, Han Z, Lin W, Li L, Hung M. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival Oncogene. 28: 3286-3295. DOI: 10.1038/Onc.2009.187 |
0.314 |
|
| 2008 |
Lee C, Dhillon J, Wang MY, Gao Y, Hu K, Park E, Astanehe A, Hung MC, Eirew P, Eaves CJ, Dunn SE. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Research. 68: 8661-6. PMID 18974106 DOI: 10.1158/0008-5472.Can-08-1082 |
0.356 |
|
| 2008 |
Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, Lee MH, Xiao C, Vassilopoulos A, Chen W, Gardner K, Man YG, Hung MC, Finkel T, Deng CX. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Molecular Cell. 32: 11-20. PMID 18851829 DOI: 10.1016/J.Molcel.2008.09.011 |
0.336 |
|
| 2008 |
Lee DF, Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5656-62. PMID 18794072 DOI: 10.1158/1078-0432.CCR-08-0123 |
0.301 |
|
| 2008 |
Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, ... ... Hung MC, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Research. 68: 6109-17. PMID 18676833 DOI: 10.1158/0008-5472.CAN-08-0579 |
0.342 |
|
| 2008 |
Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 13: 385-93. PMID 18455122 DOI: 10.1016/J.Ccr.2008.03.015 |
0.302 |
|
| 2007 |
Liao Y, Yu D, Hung MC. Novel approaches for chemosensitization of breast cancer cells: the E1A story. Advances in Experimental Medicine and Biology. 608: 144-69. PMID 17993239 DOI: 10.1007/978-0-387-74039-3_11 |
0.343 |
|
| 2007 |
Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Research. 67: 9066-76. PMID 17909010 DOI: 10.1158/0008-5472.CAN-07-0575 |
0.347 |
|
| 2007 |
Wang X, Zheng M, Liu G, Xia W, McKeown-Longo PJ, Hung MC, Zhao J. Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Research. 67: 7184-93. PMID 17671186 DOI: 10.1158/0008-5472.Can-06-4729 |
0.329 |
|
| 2006 |
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice. Oncology. 3: 269-80. PMID 16683005 DOI: 10.1038/Ncponc0509 |
0.324 |
|
| 2006 |
Yu Z, Xia W, Wang HY, Wang SC, Pan Y, Kwong KY, Hortobagyi GN, Hung MC. Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Molecular Carcinogenesis. 45: 667-75. PMID 16652376 DOI: 10.1002/mc.20212 |
0.342 |
|
| 2006 |
Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Therapy. 13: 706-19. PMID 16514421 DOI: 10.1038/sj.cgt.7700945 |
0.31 |
|
| 2006 |
Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics. 5: 317-28. PMID 16505105 DOI: 10.1158/1535-7163.Mct-05-0350 |
0.338 |
|
| 2006 |
Chen IF, Ou-Yang F, Hung JY, Liu JC, Wang H, Wang SC, Hou MF, Hortobagyi GN, Hung MC. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Molecular Cancer Therapeutics. 5: 1-7. PMID 16432157 DOI: 10.1158/1535-7163.Mct-05-0310 |
0.305 |
|
| 2006 |
Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Research and Treatment. 95: 211-8. PMID 16261406 DOI: 10.1007/s10549-005-9011-0 |
0.325 |
|
| 2005 |
Wang SC, Hung MC. Cytoplasmic/nuclear shuttling and tumor progression. Annals of the New York Academy of Sciences. 1059: 11-5. PMID 16382038 DOI: 10.1196/annals.1339.002 |
0.323 |
|
| 2005 |
Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Research. 65: 8406-13. PMID 16166319 DOI: 10.1158/0008-5472.CAN-05-1754 |
0.314 |
|
| 2005 |
Lo HW, Day CP, Hung MC. Cancer-Specific Gene Therapy Advances in Genetics. 54: 233-255. PMID 16096014 DOI: 10.1016/S0065-2660(05)54010-0 |
0.339 |
|
| 2005 |
Xie X, Li Z, Ding Q, Kuo H, Abbruzzese JL, Hung M. 82. Targeted Pancreatic Cancer-Specific Gene Therapy Controlled by a Molecular-Engineered Human Cholecystokinin Type-A Receptor (CCKAR) Promoter in In Vivo Imaging Models Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.060 |
0.317 |
|
| 2004 |
Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 6: 459-69. PMID 15542430 DOI: 10.1016/J.Ccr.2004.09.027 |
0.314 |
|
| 2004 |
Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Therapy. 11: 740-7. PMID 15359286 DOI: 10.1038/sj.cgt.7700752 |
0.306 |
|
| 2004 |
Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Research. 64: 3981-6. PMID 15173011 DOI: 10.1158/0008-5472.Can-03-3900 |
0.308 |
|
| 2004 |
Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 117: 225-37. PMID 15084260 DOI: 10.1016/S0092-8674(04)00302-2 |
0.31 |
|
| 2004 |
Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Research. 64: 2343-6. PMID 15059883 DOI: 10.1158/0008-5472.Can-03-3856 |
0.308 |
|
| 2004 |
Lee CM, Lo HW, Shao RP, Wang SC, Xia W, Gershenson DM, Hung MC. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Research. 64: 1788-93. PMID 14996741 DOI: 10.1158/0008-5472.CAN-03-2551 |
0.31 |
|
| 2004 |
Day C, Rau K, Hung M. [abstract] Selective breast tumor growth suppression mediated by the enhanced breast cancer-specific promoter Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.237 |
0.327 |
|
| 2003 |
Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Seminars in Oncology. 30: 38-48. PMID 14613025 DOI: 10.1053/J.SEMINONCOL.2003.08.006 |
0.32 |
|
| 2003 |
Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy Drug Resistance Updates. 6: 129-136. PMID 12860460 DOI: 10.1016/S1368-7646(03)00040-2 |
0.335 |
|
| 2002 |
Asada S, Choi Y, Yamada M, Wang SC, Hung MC, Qin J, Uesugi M. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proceedings of the National Academy of Sciences of the United States of America. 99: 12747-52. PMID 12242338 DOI: 10.1073/pnas.202162199 |
0.33 |
|
| 2002 |
Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 21: 5224-32. PMID 12149644 DOI: 10.1038/Sj.Onc.1205660 |
0.328 |
|
| 2002 |
Hung MC. Translational research: E1A cancer gene therapy and β-catenin as a prognostic marker Drugs of Today. 38: 21-35. |
0.316 |
|
| 2001 |
Hung M, Yan D, Zhang S. E1A-Mediated Gene Therapy. Methods in Molecular Medicine. 39: 775-782. PMID 21340839 DOI: 10.1385/1-59259-071-3:775 |
0.311 |
|
| 2001 |
Wang SC, Hung MC. HER2 overexpression and cancer targeting Seminars in Oncology. 28: 115-124. PMID 11706403 DOI: 10.1016/S0093-7754(01)90289-1 |
0.357 |
|
| 2001 |
Wang SC, Makino K, Xia W, Kim JS, Im SA, Peng H, Mok SC, Singletary SE, Hung MC. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway Oncogene. 20: 6960-6964. PMID 11687976 DOI: 10.1038/sj.onc.1204873 |
0.374 |
|
| 2001 |
Yang HY, Shao R, Hung MC, Lee MH. p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis Oncogene. 20: 3695-3702. PMID 11439332 DOI: 10.1038/sj.onc.1204472 |
0.328 |
|
| 2001 |
Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 19: 6115-21. PMID 11156524 DOI: 10.1038/Sj.Onc.1203972 |
0.341 |
|
| 2000 |
Hung M, Wang S. Suppressing HER2/neu-mediated cell transformation by transcriptional repressors. Breast Disease. 11: 133-144. PMID 15687599 DOI: 10.3233/Bd-1999-11112 |
0.361 |
|
| 2000 |
Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, Chernoff J, Hung MC, Kumar R. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. The Journal of Biological Chemistry. 275: 36238-44. PMID 10945974 DOI: 10.1074/Jbc.M002138200 |
0.314 |
|
| 2000 |
Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays. 22: 673-680. PMID 10878580 DOI: 10.1002/1521-1878(200007)22:7<673::Aid-Bies10>3.0.Co;2-A |
0.308 |
|
| 2000 |
Hung MC, Wang SC. Suppressing HER2/neu-mediated cell transformation by transcriptional repressors Breast Disease. 11: 133-144. |
0.36 |
|
| 1999 |
Hung MC, Lau YK. Basic science of HER-2/neu: A review Seminars in Oncology. 26: 51-59. PMID 10482194 |
0.385 |
|
| 1999 |
Tari AM, Hung MC, Li K, Lopez-Berestein G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene. 18: 1325-32. PMID 10022814 DOI: 10.1038/Sj.Onc.1202422 |
0.343 |
|
| 1998 |
Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 16: 2087-94. PMID 9572489 DOI: 10.1038/Sj.Onc.1201729 |
0.311 |
|
| 1997 |
Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 15: 953-60. PMID 9285690 DOI: 10.1038/Sj.Onc.1201250 |
0.329 |
|
| 1997 |
Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 14: 561-8. PMID 9053854 DOI: 10.1038/Sj.Onc.1200861 |
0.341 |
|
| 1996 |
Miller SJ, Xing X, Xi L, Hung MC. Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. Dna and Cell Biology. 15: 749-57. PMID 8836033 DOI: 10.1089/DNA.1996.15.749 |
0.313 |
|
| 1996 |
Xie Y, Hung MC. p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression Biochemical and Biophysical Research Communications. 221: 140-145. PMID 8660324 DOI: 10.1006/bbrc.1996.0559 |
0.35 |
|
| Show low-probability matches. |